Sherwood Park, CA, United States of America

Tim G Elford



 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 19(Granted Patents)


Location History:

  • Sherwood Park, CA (2017)
  • Sherwood Park, CA (US) (2019)
  • Alberta, CA (2022)

Company Filing History:


Years Active: 2017-2022

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Tim G Elford: Innovator in Pharmaceutical Chemistry

Introduction

Tim G Elford is a notable inventor based in Sherwood Park, Canada. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of Syk inhibitors. With a total of 3 patents to his name, Elford's work has had a considerable impact on drug development.

Latest Patents

Elford's latest patents include innovative formulations such as "Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors." This patent details the polymorphs of a bis-mesylate salt of a compound of Formula IA, along with processes for making these polymorphs and methods of use. Another significant patent focuses on the polymorphs of a bis-mesylate salt of a compound of Formula I or a hydrate thereof, providing compositions, methods for their preparation, and applications for such polymorphs.

Career Highlights

Throughout his career, Tim G Elford has worked with prominent companies in the pharmaceutical industry, including Gilead Connecticut, Inc. and Kronos Bio, Inc. His expertise in drug formulation and development has positioned him as a valuable asset in these organizations.

Collaborations

Elford has collaborated with several professionals in his field, including Peter Chee-Chu Fung and Michael Laird Hurrey. These collaborations have further enhanced his research and development efforts.

Conclusion

Tim G Elford is a distinguished inventor whose work in pharmaceutical chemistry continues to influence the industry. His innovative patents and collaborations reflect his commitment to advancing drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…